Ausgabe 1/2019
Inhalt (8 Artikel)
Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
- T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
Myo Htut
The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders
- T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)
Jennifer Crombie, Philippe Armand
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
- Stem Cell Transplantation (R Maziarz, Section Editor)
Bronwen E. Shaw
Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?
- Stem Cell Transplantation (R Maziarz, Section Editor)
Sarah A. Holstein, Vera J. Suman, Philip L. McCarthy
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
- Stem Cell Transplantation (R Maziarz, Section Editor)
Shalin Kothari, Jens Hillengass, Philip L. McCarthy, Sarah A. Holstein
Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy
- Stem Cell Transplantation (R Maziarz, Section Editor)
Stacie Ittershagen, Solveig Ericson, Lamis Eldjerou, Ali Shojaee, Eric Bleickardt, Manisha Patel, Tetiana Taran, Oezlem Anak, Charlene Hall, Mimi Leung, Deborah Roccoberton, Florence Salmon, Miriam Fuchs, Vadim Romanov, David Lebwohl
Treatment-Free Remission in CML: the US Perspective
- Chronic Myeloid Leukemias (M Mauro, Section Editor)
Guru Subramanian Guru Murthy, Ehab Atallah
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors
- Correction
Roberta Zappasodi, Jedd D. Wolchok, Taha Merghoub